Haleon Falls After Weak Cold and Flu Season Drags Year-End Sales

Haleon Plc slid the most in nearly one year after sales grew less than expected in 2025, as a weak cold and flu season meant fewer customers purchased its over-the-counter medicines.

The maker of Panadol and Advil painkillers said Wednesday that sales increased by 3% in 2025. That fell shy of analysts’ estimates for a 3.3% rise, and the company’s own reduced outlook for 3.5% growth.